Clinical Trials

Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

Condition:   Arthritis, Juvenile Rheumatoid
Intervention:   Drug: Sulfasalazine
Sponsor:   Pfizer
Terminated

Tue, 18 Mar 2008 12:00:00 EDT

Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma

Conditions:   Glioma;   Glioblastoma;   Recurrent Glioblastoma
Intervention:   Drug: Sulfasalazine
Sponsors:   Haukeland University Hospital;   Norwegian Cancer Society;   Northwell Health;   Weill Medical College of Cornell University;   University of Bergen;   Helse Stavanger HF
Recruiting

Thu, 19 Dec 2019 12:00:00 EST

Effects of Sulfasalazine on BOLD Response to Alcohol Cues

Condition:   Alcohol Dependence
Interventions:   Drug: Sulfasalazine;   Drug: Placebo
Sponsor:   The Mind Research Network
Completed

Thu, 10 Mar 2011 12:00:00 EST

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

Condition:   Brain Tumor
Intervention:   Drug: Sulfasalazine
Sponsor:   University of Alabama at Birmingham
Completed

Mon, 16 Apr 2012 12:00:00 EDT

Drug-drug Interaction Study With GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

Condition:   Healthy
Interventions:   Drug: Sulfasalazine;   Drug: GLPG3970
Sponsor:   Galapagos NV
Completed

Fri, 22 Jan 2021 12:00:00 EST

Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients

Conditions:   Breast Cancer;   Chronic Pain Due to Malignancy (Finding)
Interventions:   Drug: Sulfasalazine;   Drug: Placebos
Sponsor:   University of Arizona
Recruiting

Wed, 20 Feb 2019 12:00:00 EST

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Condition:   Primary Sclerosing Cholangitis
Interventions:   Drug: Sulfasalazine;   Drug: Placebo
Sponsor:   Brigham and Women's Hospital
Recruiting

Tue, 19 Jun 2018 12:00:00 EDT

Sulfasalazine and Endothelial Function

Condition:   Coronary Artery Disease
Intervention:   Drug: Sulfasalazine
Sponsor:   Boston University
Completed

Tue, 06 Nov 2007 12:00:00 EST

Real-World Emulation of the SWEFOT Trial

Condition:   Rheumatoid Arthritis
Interventions:   Biological: Infliximab;   Drug: Sulfasalazine + Hydroxychloroquine
Sponsors:   Karolinska Institutet;   Harvard Medical School
Completed

Tue, 21 Sep 2021 12:00:00 EDT

Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy

Conditions:   Diarrhea;   Gastrointestinal Complications;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: sulfasalazine;   Other: placebo
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Thu, 09 Sep 2010 12:00:00 EDT

Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Methotrexate plus sulfasalazine;   Drug: Leflunomide
Sponsor:   Singapore General Hospital
Terminated

Tue, 07 Aug 2012 12:00:00 EDT

Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)

Condition:   Moderate to Severe Active Axial Spondyloarthritis
Interventions:   Drug: Etanercept 25mg;   Drug: Sulfasalazine
Sponsors:   Charite University, Berlin, Germany;   Wyeth is now a wholly owned subsidiary of Pfizer
Unknown status

Fri, 13 Feb 2009 12:00:00 EST

Study of Sulfasalazine in Treating Painful Neuropathy

Condition:   Painful Neuropathy
Interventions:   Drug: Sulfasalazine;   Drug: placebo
Sponsor:   Massachusetts General Hospital
Terminated

Fri, 17 Aug 2012 12:00:00 EDT

Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: Sulfasalazine;   Drug: Ambrisentan;   Drug: Sulfasalazine's placebo;   Drug: Ambrisentan's placebo
Sponsor:   RenJi Hospital
Recruiting

Thu, 27 Aug 2020 12:00:00 EDT

Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Leflunomide;   Drug: Methotrexate-Sulfasalazine-Hydroxychloroquine;   Drug: Leflunomide-Sulfasalazine-Hydroxychloroquine
Sponsor:   University of Nebraska
Completed

Mon, 24 Dec 2007 12:00:00 EST

Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis

Condition:   Ankylosing Spondylitis
Interventions:   Drug: etanercept;   Drug: sulphasalazine (SSZ)
Sponsor:   Wyeth is now a wholly owned subsidiary of Pfizer
Completed

Wed, 02 Nov 2005 12:00:00 EST

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

Condition:   Drug Interaction Potentiation
Interventions:   Drug: Vadadustat;   Drug: Simvastatin;   Drug: Rosuvastatin;   Drug: Atorvastatin;   Drug: Pravastatin;   Drug: Sulfasalazine
Sponsor:   Akebia Therapeutics
Completed

Fri, 11 Jan 2019 12:00:00 EST

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

Condition:   Chemotherapy-induced Nausea and Vomiting
Interventions:   Drug: Rolapitant;   Drug: Digoxin;   Drug: Sulfasalazine;   Drug: Cooperstown Cocktail
Sponsor:   Tesaro, Inc.
Completed

Tue, 05 May 2015 12:00:00 EDT

Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis

Condition:   Ankylosing Spondylitis
Interventions:   Biological: TNF alpha;   Drug: NSAIDs and sulfasalazine
Sponsor:   Chung Shan Medical University
Unknown status

Thu, 28 May 2015 12:00:00 EDT

Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums

Conditions:   Pharmacokinetics;   Magnetic Resonance Imaging;   Administration, Oral
Interventions:   Drug: Paracetamol;   Drug: Sulfasalazine;   Drug: Fexofenadine;   Drug: Valsartan;   Device: non-caloric water;   Device: caloric drink;   Device: grapefruit juice
Sponsor:   University Medicine Greifswald
Completed

Fri, 06 Jan 2017 12:00:00 EST

Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain

Condition:   Seronegative Spondyloarthropathies
Interventions:   Drug: Methotrexate, Hydroxychloroquine;   Drug: Placebo
Sponsor:   Sanjay Gandhi Postgraduate Institute of Medical Sciences
Completed

Tue, 29 Dec 2009 12:00:00 EST

Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS

Condition:   Ankylosing Spondylitis
Intervention:   Drug: Yisaipu®
Sponsor:   Nanfang Hospital of Southern Medical University
Completed

Fri, 26 Jan 2018 12:00:00 EST

Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis

Condition:   Early Ankylosing Spondylitis
Interventions:   Drug: Tripterygium;   Drug: Sulfasalazine;   Drug: placebo
Sponsor:   Sun Yat-sen University
Unknown status

Wed, 29 Apr 2009 12:00:00 EDT

A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677

Condition:   Healthy Volunteer
Interventions:   Drug: CC-99677;   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Itraconazole;   Drug: Rifampin;   Drug: Midazolam;   Drug: Digoxin;   Drug: Metformin;   Drug: Rosuvastatin
Sponsor:   Celgene
Completed

Thu, 13 Feb 2020 12:00:00 EST

Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Etanercept , Methotrexate;   Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide
Sponsor:   Wyeth is now a wholly owned subsidiary of Pfizer
Completed

Mon, 15 Jan 2007 12:00:00 EST

A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: Sirukumab 100 mg;   Drug: Sirukumab 50 mg;   Drug: Placebo
Sponsors:   Janssen Pharmaceutical K.K.;   GlaxoSmithKline
Completed

Fri, 21 Sep 2012 12:00:00 EDT

Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis

Condition:   Ankylosing Spondylitis
Interventions:   Drug: etanercept (Half-Dose);   Drug: etanercept (Full-Dose);   Drug: Sulfasalazine;   Drug: Celecoxib
Sponsor:   Zhixiang Huang
Unknown status

Wed, 23 Dec 2015 12:00:00 EST

Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis

Conditions:   Rheumatoid Arthritis;   Stiffness, Aortic;   Endothelial Dysfunction;   Cardiovascular Risk Factor
Interventions:   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Other DMARDs
Sponsors:   Flinders University;   University of South Australia;   medac GmbH
Recruiting

Fri, 18 Aug 2017 12:00:00 EDT

Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Methotrexate;   Drug: Leflunomide;   Drug: Hydroxychloroquine;   Drug: Prednisolone;   Drug: Folic Acid;   Drug: Sulfasalazine
Sponsor:   Jawaharlal Institute of Postgraduate Medical Education & Research
Terminated

Wed, 12 Oct 2016 12:00:00 EDT

Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine

Condition:   Rheumatoid Arthritis
Intervention:   Drug: TwHF
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed

Fri, 06 Jun 2003 12:00:00 EDT

AMS INSIGHT 1 Study - Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment

Condition:   Peripheral Artery Disease
Interventions:   Device: MAGIC EXPLORER (Biotronik AG);   Device: PLEON EXPLORER (Biotronik AG)
Sponsors:   Flanders Medical Research Program;   Biotronik SE & Co. KG
Completed

Thu, 13 Dec 2007 12:00:00 EST

Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Benepali;   Drug: Sulfasalazine;   Drug: Methotrexate;   Drug: Hydroxychloroquine
Sponsors:   University of Leeds;   Samsung Bioepis Co., Ltd.
Not yet recruiting

Wed, 23 Jan 2019 12:00:00 EST

Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)

Condition:   Rheumatoid Arthritis
Interventions:   Biological: infliximab;   Drug: DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
Sponsors:   Merck Sharp & Dohme Corp.;   AESCA Pharma GmbH
Terminated

Tue, 28 Aug 2007 12:00:00 EDT

Treatments Against RA and Effect on FDG-PET/CT

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Hydroxychloroquine;   Drug: Etanercept;   Drug: Adalimumab
Sponsors:   Brigham and Women's Hospital;   Columbia University
Active, not recruiting

Fri, 27 Feb 2015 12:00:00 EST

Psoriatic Oligoarthritis Intervention With Symptomatic thErapy

Condition:   Psoriatic Arthritis
Interventions:   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Leflunomide;   Drug: Methylprednisolone;   Drug: Triamcinolone
Sponsors:   University of Oxford;   National Institute for Health Research, United Kingdom
Completed

Wed, 09 Jan 2019 12:00:00 EST

Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Combination Steroid;   Drug: Methotrexate;   Drug: Combination
Sponsor:   All India Institute of Medical Sciences, New Delhi
Completed

Wed, 05 Jun 2013 12:00:00 EDT

Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis

Conditions:   Ankylosing Spondylitis;   Treatment
Intervention:   Drug: kunxian capsule
Sponsors:   Gu Jieruo;   China-Japan Friendship Hospital;   Dongguan People's Hospital;   Zhujiang Hospital;   Huashan Hospital
Completed

Thu, 06 Aug 2009 12:00:00 EDT

TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;   Drug: Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
Sponsors:   University of Helsinki;   Seinajoki Central Hospital;   Oulu University Hospital;   Jyväskylä Central Hospital;   Kuopio University Hospital;   Satakunta Central Hospital;   University of Turku;   Rheumatism Foundation Hospital;   Orton Invalid Foundation;   South Carelia Central Hospital;   Lappi Central Hospital;   Kanta-Häme Central Hospital
Unknown status

Mon, 25 May 2009 12:00:00 EDT

Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Leflunomide;   Drug: Prednisone
Sponsors:   P. Verschueren;   Agentschap voor Innovatie door Wetenschap en Technologie
Completed

Fri, 30 Jul 2010 12:00:00 EDT

Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial

Condition:   Psoriatic Arthritis
Interventions:   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Leflunomide;   Drug: Adalimumab
Sponsor:   University of Oxford
Recruiting

Wed, 14 Nov 2018 12:00:00 EST

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Etanercept;   Drug: methotrexate;   Drug: Sulfasalazine;   Drug: Hydroxychloroquine;   Drug: Placebo, triple;   Drug: Placebo, etanercept
Sponsors:   US Department of Veterans Affairs;   Canadian Institutes of Health Research (CIHR);   Rheumatoid Arthritis Investigational Network (RAIN);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed

Thu, 30 Nov 2006 12:00:00 EST

Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)

Condition:   Rheumatoid Arthritis
Interventions:   Drug: conventional DMARD combination;   Biological: MTX plus anti-TNF
Sponsor:   Karolinska Institutet
Completed

Thu, 02 Oct 2008 12:00:00 EDT

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

Condition:   Rheumatoid Arthritis
Interventions:   Drug: methotrexate;   Drug: sulfasalazine;   Drug: hydroxychloroquine;   Drug: etanercept
Sponsors:   University of Alabama at Birmingham;   Amgen;   Barr Laboratories;   Pfizer
Completed

Tue, 29 Nov 2005 12:00:00 EST

Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Sulphasalazine + Hydroxychloroquine OR Prednisolone;   Biological: Cimzia;   Biological: Orencia;   Biological: RoActemra
Sponsor:   Karolinska Institutet
Active, not recruiting

Tue, 09 Jun 2015 12:00:00 EDT

Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs

Conditions:   Ankylosing Spondylitis;   Spondyloarthritis
Interventions:   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Hydroxychloroquine;   Drug: Etanercept (50mg per week, for 4 weeks);   Drug: Etanercept (50mg per week, for 2 weeks);   Drug: Etanercept (50mg per week)
Sponsor:   Nanfang Hospital of Southern Medical University
Not yet recruiting

Wed, 04 Sep 2019 12:00:00 EDT

Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis

Condition:   Ankylosing Spondyloarthritis
Interventions:   Drug: Adalimumab;   Other: PET/CT imaging
Sponsors:   University of Helsinki;   AbbVie
Unknown status

Fri, 18 Dec 2015 12:00:00 EST

Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery

Conditions:   Esophageal Cancer;   Nutrition Disorders;   Appetite Disorders;   Dumping Syndrome;   Delayed Gastric Emptying;   Surgery
Interventions:   Drug: Octreotide Acetate;   Drug: Saline Solution;   Drug: Paracetamol;   Drug: Sulfasalazine;   Diagnostic Test: Duodenal biopsy
Sponsor:   St. James's Hospital, Ireland
Completed

Thu, 08 Nov 2018 12:00:00 EST

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Sarilumab;   Drug: placebo;   Drug: hydroxychloroquine;   Drug: methotrexate;   Drug: sulfasalazine;   Drug: leflunomide
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Completed

Thu, 18 Oct 2012 12:00:00 EDT

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Condition:   Rheumatoid Arthritis
Interventions:   Drug: sarilumab SAR153191 (REGN88);   Drug: tocilizumab;   Drug: hydroxychloroquine;   Drug: methotrexate;   Drug: sulfasalazine;   Drug: leflunomide;   Drug: subcutaneous placebo;   Drug: intravenous placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Completed

Tue, 15 Jan 2013 12:00:00 EST

Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

Condition:   Rheumatoid Arthritis
Interventions:   Drug: methotrexate;   Drug: sulfasalazine;   Drug: abatacept;   Drug: tocilizumab;   Drug: tofacitinib/baricitinib
Sponsor:   Vastra Gotaland Region
Recruiting

Thu, 22 Feb 2018 12:00:00 EST

A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Azathioprine;   Drug: Chloroquine;   Drug: Hydroxychloroquine;   Drug: Leflunomide;   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Tocilizumab
Sponsor:   Hoffmann-La Roche
Completed

Fri, 13 Sep 2013 12:00:00 EDT

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

Condition:   RA
Interventions:   Drug: Sarilumab;   Device: Auto-Injector Device (AID);   Device: Pre-filled Syringe (PFS);   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Leflunomide;   Drug: Hydroxychloroquine
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Completed

Fri, 07 Feb 2014 12:00:00 EST

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Sarilumab;   Drug: Sulfasalazine;   Drug: Leflunomide;   Drug: Bucillamine;   Drug: Tacrolimus;   Drug: Mizoribine
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Completed

Thu, 26 Feb 2015 12:00:00 EST

RICE: Remission by Intra-articular Injection Plus CErtolizumab

Condition:   Rheumatoid Arthritis
Intervention:   Drug: Certolizumab Pegol
Sponsors:   Rüdiger B. Müller;   UCB Pharma
Completed

Tue, 18 Nov 2014 12:00:00 EST

Combination Therapy Prevents the Relapse of RA

Condition:   Recurrence (Disease Attribute)
Interventions:   Drug: Entanercept;   Drug: HCQ;   Drug: MTX
Sponsors:   Peking University First Hospital;   Peking University People's Hospital;   Peking University Third Hospital;   Beijing Hospital;   Beijing Jishuitan Hospital;   Peking University Shougang Hospital;   Beijing Shijitan Hospital, Capital Medical University
Recruiting

Fri, 19 Dec 2014 12:00:00 EST

Very Early Versus Delayed Etanercept in Patients With RA

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Etanercept;   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Hydroxychloroquine
Sponsor:   University of Leeds
Completed

Mon, 04 May 2015 12:00:00 EDT

An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement

Condition:   Spondylitis, Ankylosing
Interventions:   Drug: Infliximab;   Drug: NSAIDs;   Drug: DMARDs
Sponsor:   Janssen Research & Development, LLC
Terminated

Tue, 18 Nov 2014 12:00:00 EST

Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Conditions:   Psoriatic Arthritis;   Withdrawal;   Reduction
Interventions:   Drug: Prednisolone;   Drug: Sulfasalazine;   Drug: Leflunomide;   Drug: Methotrexate;   Drug: Tofacitinib;   Drug: Apremilast;   Drug: Etanercept;   Drug: Adalimumab;   Drug: Infliximab;   Drug: Certolizumab pegol;   Drug: Golimumab;   Drug: Abatacept;   Drug: Secukinumab;   Drug: Ixekizumab;   Drug: Ustekinumab
Sponsor:   University of Erlangen-Nürnberg Medical School
Not yet recruiting

Fri, 30 Oct 2020 12:00:00 EDT

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

Conditions:   Psoriasis;   Inflammatory Bowel Diseases
Interventions:   Drug: TNF-alpha inhibitors;   Drug: Alternative/no medication;   Other: Alternative/no medication;   Drug: Purine/folic acid analogues
Sponsor:   Medical University of Vienna
Completed

Tue, 03 Mar 2015 12:00:00 EST

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

Condition:   Rheumatoid Arthritis
Interventions:   Drug: AZD9056;   Drug: Etanercept;   Drug: Placebo
Sponsor:   AstraZeneca
Completed

Fri, 24 Aug 2007 12:00:00 EDT

Anti-TNF Therapy and Nerve Conduction Studies in Ankylosing Spondylitis

Conditions:   Anti - TNF Therapy;   Ankylosing Spondylitis;   Neuropathy
Interventions:   Drug: Anti-TNF agents;   Drug: Conventional therapy users for the last 5 years
Sponsor:   Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Completed

Tue, 29 Jun 2021 12:00:00 EDT

Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.

Condition:   Intestinal Obstruction
Interventions:   Drug: Loperamide placebo;   Drug: Loperamide;   Device: Colon Transit;   Drug: Sulfasalazine;   Drug: Placebo of MNTX and NLX;   Drug: Naloxone;   Drug: Methylnaltrexone
Sponsor:   University Medicine Greifswald
Completed

Fri, 11 May 2012 12:00:00 EDT

Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis

Condition:   Juvenile Idiopathic Arthritis
Interventions:   Drug: Infliximab plus methotrexate;   Drug: Combination of DMARDs;   Drug: Methotrexate alone
Sponsors:   Helsinki University Central Hospital;   Foundation for Paediatric Research, Finland;   Päivikki and Sakari Sohlberg Foundation, Finland;   Rheumatism Foundation Hospital;   Scandinavian Rheumatology Research Foundation;   Paijat-Hame Hospital District
Completed

Wed, 18 Nov 2009 12:00:00 EST

Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects

Condition:   Intestinal Obstruction
Interventions:   Drug: Loperamide;   Drug: Loperamide placebo;   Drug: Methylnaltrexone placebo;   Drug: Methylnaltrexone 12 mg sc.;   Drug: Methylnaltrexone IR capsule;   Drug: Methylnaltrexone ER capsule;   Device: Colon Transit;   Drug: Sulfasalazine
Sponsor:   University Medicine Greifswald
Completed

Fri, 11 May 2012 12:00:00 EDT

Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea

Condition:   Ulcerative Colitis
Intervention:   Other: PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA)
Sponsor:   Ferring Pharmaceuticals
Not yet recruiting

Wed, 05 Aug 2020 12:00:00 EDT

Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients

Conditions:   Rheumatoid Arthritis;   COVID
Intervention:   Drug: Traditional antirheumatic drugs
Sponsor:   Sadat City University
Enrolling by invitation

Tue, 16 Jun 2020 12:00:00 EDT

Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Ankylosing Spondylitis (AS)

Condition:   Ankylosing Spondylitis
Intervention:   Biological: Human umbilical cord-derived MSCs
Sponsor:   Shandong University
Unknown status

Fri, 19 Aug 2011 12:00:00 EDT

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Condition:   Rheumatoid Arthritis
Interventions:   Other: Lab Work;   Drug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg);   Drug: Certolizumab pegol (CDP870, tradename Cimzia);   Drug: Hydroxychloroquine;   Drug: Sulfasalazine;   Drug: Medrol;   Drug: Prednisone;   Drug: Triamcinolone;   Drug: Naproxen;   Drug: Leflunomide;   Drug: Methotrexate;   Drug: humira
Sponsors:   University of Illinois at Chicago;   UCB Pharma
Completed

Fri, 22 May 2015 12:00:00 EDT

Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)

Condition:   Rheumatoid Arthritis
Intervention:   Drug: DMARD cessation
Sponsors:   Newcastle-upon-Tyne Hospitals NHS Trust;   Newcastle University;   Wellcome Trust
Completed

Mon, 18 Aug 2014 12:00:00 EDT

The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Intervention:   Drug: Tofacitinib
Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting

Tue, 15 Jun 2021 12:00:00 EDT

A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS

Conditions:   Ankylosing Spondylitis;   Therapeutic Agent Toxicity
Interventions:   Procedure: intermittent treatment;   Procedure: continuous treatment
Sponsors:   Shanghai Zhongshan Hospital;   Wu Jieping Medical Foundation
Recruiting

Tue, 26 May 2020 12:00:00 EDT

Extension Study Evaluating Etanercept in Ankylosing Spondylitis

Condition:   Ankylosing Spondylitis
Intervention:   Drug: Enbrel (etanercept)
Sponsor:   Wyeth is now a wholly owned subsidiary of Pfizer
Completed

Tue, 12 Dec 2006 12:00:00 EST

Patients Response to Early Switch To Oral:Osteomyelitis Study

Condition:   Osteomyelitis
Interventions:   Drug: oral antibiotics;   Procedure: intravenous antibiotics
Sponsors:   Julio Ramirez;   University of Louisville
Terminated

Fri, 28 Mar 2014 12:00:00 EDT

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Interventions:   Drug: SARILUMAB;   Drug: Azathioprine;   Drug: Chloroquine;   Drug: Hydroxychloroquine;   Drug: Leflunomide;   Drug: Methotrexate;   Drug: Sulfasalazine
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Completed

Wed, 28 Feb 2018 12:00:00 EST

CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)

Conditions:   Chronic Nonbacterial Osteomyelitis;   Chronic Recurrent Multifocal Osteomyelitis
Interventions:   Drug: Methotrexate;   Drug: Sulfasalazine;   Drug: Leflunomide;   Drug: Pamidronate;   Drug: Zoledronic acid;   Drug: Etanercept;   Drug: Adalimumab;   Drug: Certolizumab;   Drug: Infliximab;   Drug: Golimumab
Sponsors:   Seattle Children's Hospital;   Boston Children's Hospital, Boston, MA, USA;   Hospital for Special Surgery, New York City, NY, USA;   Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA;   Riley Children's Hospital, Indianapolis, IN, USA;   University of North Carolina, Chapel Hill, NC, USA;   Royal Children's Hospital, Melbourne, Australia;   Hacettepe University, Ankara, Turkey;   Bambino Gesù Children's Hospital, Rome, Italy;   University of British Columbia, Vancouver, BC, Canada;   Meyer Children's Hospital, Florence, Italy;   Mansoura University
Recruiting

Tue, 26 Jan 2021 12:00:00 EST

Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade

Condition:   Peripheral Spondyloarthritis
Interventions:   Drug: week 24;   Drug: week 36;   Drug: Week 48;   Drug: Week 60
Sponsors:   University Hospital, Ghent;   Merck Sharp & Dohme Corp.
Recruiting

Wed, 17 Jun 2020 12:00:00 EDT

Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis

Condition:   Psoriatic Arthritis
Intervention:   Drug: Methotrexate
Sponsors:   University of Oxford;   National Institute for Health Research, United Kingdom
Recruiting

Mon, 21 May 2018 12:00:00 EDT

RETRO (REduction of Therapy in RA Patients in Ongoing Remission)

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Control group;   Other: Reduction group 1;   Other: Reduction group 2
Sponsor:   University of Erlangen-Nürnberg Medical School
Unknown status

Fri, 20 May 2016 12:00:00 EDT

Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy

Condition:   Rheumatoid Arthritis
Interventions:   Biological: Phase 1: Etanercept;   Drug: Phase 1: Methotrexate;   Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX;   Drug: Phase 1: Conventiaonal DMARD
Sponsors:   Pfizer;   Amgen
Completed

Fri, 20 Feb 2009 12:00:00 EST

To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Tocilizumab;   Drug: DMARDs
Sponsor:   JW Pharmaceutical
Completed

Thu, 09 Dec 2010 12:00:00 EST

Optimal MTX Dose With Folic Acid Randomized Case-control Trial

Condition:   Rheumatoid Arthritis
Interventions:   Drug: MTX;   Drug: Folic Acid;   Drug: DMARDs
Sponsors:   Sun Yat-sen University;   Shanghai Pharmaceuticals Holding Co., Ltd
Unknown status

Mon, 26 Aug 2019 12:00:00 EDT

Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects

Condition:   Rheumatoid Arthritis
Interventions:   Drug: etanercept (EnbrelTM);   Drug: methotrexate
Sponsor:   Wyeth is now a wholly owned subsidiary of Pfizer
Terminated

Mon, 30 Jun 2008 12:00:00 EDT

Metformin Use in Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Metformin;   Drug: Conventional DMARDs;   Drug: Placebo Oral Tablet
Sponsors:   Ain Shams University;   Future University in Egypt
Unknown status

Tue, 05 Mar 2019 12:00:00 EST

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

Condition:   Rheumatoid Arthritis
Interventions:   Drug: etanercept;   Drug: Placebo;   Drug: DMARD Therapy
Sponsor:   Amgen
Completed

Fri, 11 Mar 2011 12:00:00 EST

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib;   Drug: csDMARDs
Sponsors:   Gilead Sciences;   Galapagos NV
Completed

Mon, 22 Aug 2016 12:00:00 EDT

A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Condition:   Rheumatoid Arthritis (RA)
Interventions:   Drug: Peficitinib;   Drug: Plaebo;   Drug: Disease-modifying antirheumatic drugs (DMARDs)
Sponsor:   Astellas Pharma China, Inc.
Active, not recruiting

Thu, 06 Sep 2018 12:00:00 EDT

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Tocilizumab;   Drug: Placebo;   Drug: Permitted DMARDs
Sponsor:   Hoffmann-La Roche
Completed

Wed, 19 Sep 2007 12:00:00 EDT

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

Condition:   Ulcerative Colitis
Interventions:   Drug: Budesonide MMX®;   Drug: Placebo;   Drug: 5-ASA
Sponsor:   Bausch Health Americas, Inc.
Completed

Tue, 14 Feb 2012 12:00:00 EST

Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Non-biological DMARD's;   Biological: Cimzia;   Biological: Orencia;   Biological: RoActemra
Sponsor:   Karolinska Institutet
Active, not recruiting

Wed, 14 Dec 2011 12:00:00 EST

Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Condition:   Rheumatoid Arthritis
Interventions:   Drug: tocilizumab;   Drug: DMARDs;   Drug: Placebo
Sponsor:   JW Pharmaceutical
Completed

Thu, 30 Sep 2010 12:00:00 EDT

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Tocilizumab;   Drug: Disease-modifying anti-rheumatic drugs;   Drug: Non-steroidal anti-inflammatory drugs;   Drug: Oral corticosteroids
Sponsor:   Hoffmann-La Roche
Completed

Wed, 23 Jul 2008 12:00:00 EDT

Pragmatic Clinical Trials in Scleroderma

Conditions:   Scleroderma, Systemic;   Sclerosis, Systemic
Interventions:   Other: Interstitial lung disease induction algorithm;   Other: Pulmonary arterial hypertension algorithm;   Other: Raynaud's phenomenon algorithm;   Other: Digital ulcer algorithm;   Other: Inflammatory arthritis algorithm;   Other: Gastroesophageal reflux algorithm;   Other: Bacterial overgrowth algorithm;   Other: Constipation algorithm;   Other: Skin involvement algorithm;   Other: Pain algorithm
Sponsors:   University of West London;   University of Western Ontario, Canada
Unknown status

Wed, 01 Aug 2018 12:00:00 EDT